The combination determined an additive cytotoxic effect of 200–400 nM disulfiram to polatuzumab vedotin in all cell lines tested, not limited to polatuzumab vedotin‐resistant DLBCL cell lines with increased ALDH1L1 expression (Figure S4). Here, ALDH1L1 is linked to diffuse large B-cell lymphoma.